Biological therapy and the immune system in patients with chronic myeloid leukemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33142810" target="_blank" >RIV/61989592:15110/12:33142810 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1007/s12185-012-1116-8" target="_blank" >http://dx.doi.org/10.1007/s12185-012-1116-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12185-012-1116-8" target="_blank" >10.1007/s12185-012-1116-8</a>

Result language

angličtina

Original language name

Biological therapy and the immune system in patients with chronic myeloid leukemia

Original language description

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells that has been recognized as a disease responsive to immunotherapy. Despite the huge success of the tyrosine kinase inhibitors (TKIs), CML remains for the most part incurable, probably due to treatment resistance of leukemic stem cells, which are responsible for rapid disease relapse after discontinuation of therapy. Only allogeneic stem cell transplantation enables disease eradication. In addition to the Bcr-Abl1 oncoprotein, TKIs also inhibit off-target kinases (e.g. c-kit, Src, Tec), some of them having physiological functions in immune responses. In vitro studies have implied immunomodulatory effects of TKIs and interferon-alpha (IFN-a), but comprehensive information from in vivo analyses is missing. This review summarizes the recent advances in the field of immunology of CML, including basic information about leukemia-associated antigens and peptide vaccines, that could lead to the in

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT12218" target="_blank" >NT12218: Personalized treatment of chronic myeloproliferative disorders and myelodysplastic syndrome - a cellular metabolomics study.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International Journal of Hematology

ISSN

0925-5710

e-ISSN

—

Volume of the periodical

96

Issue of the periodical within the volume

1

Country of publishing house

JP - JAPAN

Number of pages

9

Pages from-to

1-9

UT code for WoS article

—

EID of the result in the Scopus database

—